Novo Nordisk sues Hims & Hers over cheaper copycat versions of Wegovy pill, injections

Healthy Returns: What’s next for Novo Nordisk’s next-generation obesity drug CagriSema after trial miss

A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Novo Nordisk isn’t catching a break this year.  Shares of the Danish drugmaker plummeted on Monday after it released data showing that its next-generation obesity drug failed…

Read More
Equinox's $40,000-a-year membership has a waiting list, says chairman Harvey Spevak

Equinox’s $40,000-a-year membership has a waiting list, says chairman Harvey Spevak

A version of this article first appeared in CNBC’s Inside Wealth newsletter with Robert Frank, a weekly guide to the high-net-worth investor and consumer. Sign up to receive future editions, straight to your inbox. Equinox’s $40,000-a-year membership has a waiting list of more than 1,000 people, as demand for luxury health and wellness programs soars, according to…

Read More
FDA chief Marty Makary says 'everything should be over-the-counter' unless drug is unsafe or addictive

FDA chief Marty Makary says ‘everything should be over-the-counter’ unless drug is unsafe or addictive

Food and Drug Administration Commissioner Marty Makary told CNBC that he believes “everything should be over-the-counter” unless a drug is unsafe, addictive or requires monitoring – doubling down on a push that some in the pharmaceutical industry have questioned.  In an interview on Wednesday in Washington, D.C., Makary said the FDA’s aims to make changes…

Read More